Loading
Further reducing chemotherapy according to biology and response, including observation alone for some infants, maintained a three-year survival of 96 percent in intermediate-risk neuroblastoma.
Children's Oncology Group phase 3 study of 404 children with intermediate-risk neuroblastoma treated with two, four or eight cycles of chemotherapy depending on stage, age, biology and response, with some subgroups receiving surgery alone.
Three-year event-free survival was 83.2 percent and overall survival 94.9 percent; 12q loss and 1p loss identified patients with more events, and reduced therapy was successful in most subgroups.
Current intermediate-risk neuroblastoma protocols minimise chemotherapy to two to eight cycles by response and biology, following this study.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/